Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea

Circulation. 2018 Aug 7;138(6):646-648. doi: 10.1161/CIRCULATIONAHA.118.034489.

Authors

Luis Ortega-Paz¹, Salvatore Brugaletta¹, Sara Ariotti², K Martijn Akkerhuis³, Alexios Karagiannis⁴, Stephan Windecker², Marco Valgimigli²; HI-TECH investigators

Affiliations

¹ Cardiovascular Clinic Institute, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Spain (L.O-P., S.B.).
² Swiss Cardiovascular Center Bern, Bern University Hospital (S.A., S.W., M.V.).
³ Erasmus University Medical Center, Rotterdam, Netherlands (K.M.A.).
⁴ Clinical Trial Unit Bern, and Institute of Social and Preventive Medicine, University of Bern, Switzerland (A.K.).

PMID: 29794083
DOI: 10.1161/CIRCULATIONAHA.118.034489

No abstract available

Keywords: P2Y12 receptors; adenosine; dyspnea; ticagrelor.

Publication types

Letter
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Acute Coronary Syndrome / blood
Acute Coronary Syndrome / diagnosis
Acute Coronary Syndrome / drug therapy*
Adenosine / blood*
Biomarkers / blood
Cross-Over Studies
Drug Monitoring / methods
Dyspnea / blood*
Dyspnea / chemically induced*
Dyspnea / diagnosis
Humans
Platelet Aggregation / drug effects
Platelet Aggregation Inhibitors / administration & dosage
Platelet Aggregation Inhibitors / adverse effects*
Platelet Aggregation Inhibitors / blood*
Platelet Function Tests
Prospective Studies
Purinergic P2Y Receptor Antagonists / administration & dosage
Purinergic P2Y Receptor Antagonists / adverse effects*
Purinergic P2Y Receptor Antagonists / blood*
Ticagrelor / administration & dosage
Ticagrelor / adverse effects*
Ticagrelor / blood*
Time Factors

Substances

Biomarkers
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Ticagrelor
Adenosine